Pediatric Obesity Pharmacotherapy

For decades, pediatric obesity management was limited to lifestyle intervention programs with modest and often unsustained weight loss. Orlistat was the first FDA-approved anti-obesity medication for adolescents (2003), but its efficacy was limited to 2-3% additional weight loss over placebo with significant gastrointestinal side effects. The rising prevalence of severe obesity in children and adolescents (now ~6% of US youth) created urgent demand for more effective pharmacological options. Early GLP-1 receptor agonist trials in adults suggested a potential therapeutic revolution.

The SCALE Teens trial published in 2020 demonstrated that liraglutide 3.0 mg daily achieved significant BMI reduction in adolescents with obesity, establishing GLP-1 receptor agonists as viable pediatric treatments. The transformative STEP TEENS trial, published in the NEJM in December 2022, showed that once-weekly semaglutide 2.4 mg produced a remarkable 16.1% reduction in BMI versus 0.6% with placebo in adolescents aged 12-17. This effect size was comparable to or greater than adult results and far exceeded any prior pharmacotherapy. The FDA approved semaglutide for adolescents aged 12+ in December 2022.

Following STEP TEENS, tirzepatide (dual GIP/GLP-1 agonist) was studied in adolescents, showing even greater BMI reductions of up to 20% in preliminary results. Semaglutide trials expanded to younger children aged 6-12 years. The AAP released its landmark 2023 Clinical Practice Guideline, fundamentally shifting the paradigm by recommending pharmacotherapy for children aged 12+ with obesity and ages 8+ in certain cases, alongside intensive health behavior and lifestyle treatment. Research into weight regain after discontinuation became a critical concern, with studies showing significant BMI rebound upon stopping GLP-1 therapy.

The AAP 2023 Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity was a paradigm-shifting document. It explicitly recommended pharmacotherapy alongside intensive health behavior and lifestyle treatment for adolescents aged 12+ with obesity, and for children aged 8+ in specific circumstances. The Endocrine Society also updated recommendations to include GLP-1 agonists. This marked a dramatic departure from lifestyle-only approaches that had dominated pediatric obesity management for decades.

Pediatric obesity pharmacotherapy is in a period of rapid expansion. Semaglutide is FDA-approved for adolescents 12+, with tirzepatide approvals anticipated. Key ongoing questions include optimal duration of therapy (likely long-term given weight regain on cessation), access and equity (cost barriers remain significant), long-term safety in growing children (bone health, growth velocity, pubertal development), and the role of combination therapy. The field is also grappling with the distinction between treating a chronic disease versus managing a lifestyle condition, as the AAP guideline firmly established obesity as a disease requiring medical treatment.